| Date: 2021.4.12 |
|---|
| Your Name: Ying Liu |
| Manuscript Title: A retrospective analysis of prognostic factors for 160 patients with stage III small cell lung cancer |
| Manuscript number (if known):APM-21-50-CL |
| |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are |
| related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third |
| parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment |
| to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a |

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | XNone | |
|-----|---|---|---|
| | manuscript writing or educational events | | |
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | XNone | |
| | pending | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | XNone | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| 12 | Receipt of equipment, | XNone | _ |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |
| | | | |
| Dle | assa summariza tha ahova c | onflict of interest in the following box: | |
| | ase summarize the above c | of interest in the following box. | |
| | None | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Date:2021.4.12 |
|--|
| Your Name: Ying Xin_ |
| Manuscript Title: A retrospective analysis of prognostic factors for 160 patients with stage III small cell lung cancer Manuscript number (if known):APM-21-50-CL |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. |
| The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> . |
| The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. |
| to take the land of the land o |

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | XNone | |
|-----|---|---|---|
| | manuscript writing or educational events | | |
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | XNone | |
| | pending | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | XNone | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| 12 | Receipt of equipment, | XNone | _ |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |
| | | | |
| Dle | assa summariza tha ahova c | onflict of interest in the following box: | |
| | ase summarize the above c | of interest in the following box. | |
| | None | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Yo Ma | - | · · · · · · | factors for 160 patients with stage III small cell lung cancer |
|-----------------|---|--|---|
| rel pa to | ated to the content of your rties whose interests may be | manuscript. "Related" me e affected by the content on necessarily indicate a bias. | Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so. |
| | e following questions apply anuscript only. | to the author's relationsh | ips/activities/interests as they relate to the <u>current</u> |
| to me | the epidemiology of hypertoedication, even if that medic | ension, you should declare ation is not mentioned in pport for the work reporte | defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items, |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initia | al planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: pas | t 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | XNone | |
|-----|---|---|---|
| | manuscript writing or educational events | | |
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | XNone | |
| | pending | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | XNone | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| 12 | Receipt of equipment, | XNone | _ |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |
| | | | |
| Dle | assa summariza tha ahova c | onflict of interest in the following box: | |
| | ase summarize the above c | of interest in the following box. | |
| | None | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Da | te:2021.4.12 | | |
|------------------------|---|---|---|
| | ur Name:Ying Wa | | |
| M | anuscript Title: A retrospecti | ive analysis of prognostic | factors for 160 patients with stage III small cell lung cancer |
| M | anuscript number (if known) |):APM-21-50-CL | |
| | | | |
| rel pa to rel | ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply | manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d | Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so. |
| <u>m</u> | anuscript only. | | |
| to me | the epidemiology of hyperto edication, even if that medic | ension, you should declare ation is not mentioned in pport for the work reporte | e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items, |
| | | Name all entities with | Specifications/Comments |
| | | whom you have this relationship or indicate none (add rows as needed) | (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initia | al planning of the work |
| l | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: pas | t 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 1 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | XNone | |
|-----|---|---|---|
| | manuscript writing or educational events | | |
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | XNone | |
| | pending | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | XNone | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| 12 | Receipt of equipment, | XNone | _ |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |
| | | | |
| Dle | assa summariza tha ahova c | onflict of interest in the following box: | |
| | ase summarize the above c | of interest in the following box. | |
| | None | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Da | te:2021.4.12 | | | |
|-----------------|---|--|---|----|
| Yo | ur Name:Xin-Ji Dai | | | |
| M | anuscript Title: A retrospecti | ive analysis of prognostic | factors for 160 patients with stage III small cell lung canc | er |
| Ma | anuscript number (if known) | :APM-21-50-CL | | |
| | | | | |
| rel pa to | ated to the content of your rties whose interests may be | manuscript. "Related" me e affected by the content necessarily indicate a bias | Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so. | |
| | e following questions apply anuscript only. | to the author's relationsh | ips/activities/interests as they relate to the <u>current</u> | |
| to me | the epidemiology of hyperto edication, even if that medic | ension, you should declare ation is not mentioned in | edefined broadly. For example, if your manuscript pertaine all relationships with manufacturers of antihypertensive the manuscript. The manuscript without time limit. For all other ite | e |
| | e time frame for disclosure i | | au in this manuscript without time mint. For an other re- | |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
| | | Time frame: Since the initia | al planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | | |
| | | | | |
| | | | | |
| | | Time frame: pas | t 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | | |
| 3 | Royalties or licenses | XNone | | |
| 4 | Consulting fees | XNone | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | XNone | |
|-----|---|---|---|
| | manuscript writing or educational events | | |
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | XNone | |
| | pending | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | XNone | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| 12 | Receipt of equipment, | XNone | _ |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |
| | | | |
| Dle | assa summariza tha ahova c | onflict of interest in the following box: | |
| | ase summarize the above c | of interest in the following box. | |
| | None | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Table 4:Univariate analysis and Cox regression analysis of OS in patients with stage III SCLC

| Factor | | Su | Surviv | χ2 | P of single | P of |
|------------------|------------|-----|---------|-------|-------------|----------|
| | | m | al time | | factor | Multiple |
| | | | median | | | factors |
| | | | (Mon | | | |
| | | | ths) | | | |
| Gender | Male | 100 | | 0.647 | 0.421 | |
| | Fenale | 60 | | | | |
| Age(years old) | ≤59 | 86 | | 2.555 | 0.110 | |
| | >59 | 74 | | | | |
| PS score | 0 | 15 | | 6.433 | 0.040 | 0.705 |
| | 1 | 134 | | | | |
| | 2 | 11 | | | | |
| Stage | IIIA stage | 103 | | 0.208 | 0.648 | |
| | IIIB stage | 57 | | | | |
| Pleural effusion | Y | 73 | | 6.803 | 0.009 | 0.059 |
| | N | 28 | | | | |
| First-line | ≤4 | 56 | | 4.987 | 0.026 | 0.015 |
| treatment cycle | >4 | 104 | | | | |
| Therapy effect | Cr | 7 | | 6.015 | 0.111 | |
| | pr | 125 | | | | |
| | sd | 27 | | | | |
| | pd | 1 | | | | |
| Radiotherapy | Y | 107 | | 4.167 | 0.041 | 0.203 |
| | N | 53 | | | | |
| Baseline LDH | Normal | 84 | | 3.781 | 0.052 | |
| | Low | 16 | | | | |
| Baseline NSE | Normal | 41 | | 0.722 | 0.396 | |

| | High | 56 | | |
|-------------------|-------------|-----|-------|-------|
| Radiotherapy | Conventio | 17 | 0.249 | 0.618 |
| ways | nal | | | |
| | irradiation | | | |
| | Conformal | 85 | | |
| | or | | | |
| | intensity-m | | | |
| | odulated | | | |
| Number of | 1-2 cycles | 67 | 1.434 | 0.231 |
| chemotherapy | 3-4 cycles | 36 | | |
| cycles before | | | | |
| radiotherapy | | | | |
| Prophylactic | Y | 144 | 1.434 | 0.231 |
| brain irradiation | N | 16 | | |

Table 1: Clinical characteristics of 160 patients with stage III SCLC

| Item | | IIIA | IIIB | X^2 | P |
|---------------------|---------------|------|------|--------|---------|
| Gender | Male | 67 | 33 | 0.801 | 0.371 |
| | Female | 36 | 24 | | |
| Age(years old) | ≤59 | 57 | 29 | 0.294 | 0.588 |
| | >59 | 46 | 28 | | |
| PS score | 0 | 10 | 5 | 7.092 | 0.029 |
| | 1 | 90 | 44 | | |
| | 2 | 3 | 8 | | |
| T staging | 1 | 7 | 2 | 26.960 | < 0.001 |
| | 2 | 46 | 15 | | |
| | 3 | 7 | 6 | | |
| | | _ | | | |
| | 4 | 2 | 17 | | |
| Supraclavicular | Y | 2 | 21 | 34.882 | < 0.001 |
| lymph node | N | 60 | 18 | | |
| metastasis | | | | | |
| Pleural effusion | Y | 13 | 15 | 3.656 | 0.056 |
| | N | 49 | 24 | | |
| Baseline LDH (no | Normal | 53 | 31 | 0.267 | 0.605 |
| new data added) | Low | 9 | 7 | | |
| Baseline NSE (no | Normal | 28 | 13 | 1.247 | 0.264 |
| new data added) | High | 32 | 24 | | |
| Radiotherapy ways | Conventional | 15 | 2 | 4.945 | 0.026 |
| | irradiation | | | | |
| | Conformal or | 51 | 34 | | |
| | intensity-mod | | | | |
| | ulated | | | | |
| Number of | 1-2 cycles | 42 | 25 | 0.015 | 0.904 |
| chemotherapy cycles | 3-4 cycles | 23 | 13 | | |

| before radiotherapy | | | | | |
|---------------------|---|----|----|-------|-------|
| Prophylactic brain | Y | 11 | 4 | 0.531 | 0.466 |
| irradiation | N | 92 | 52 | | |

| Da | ite:2021.4.12 | | |
|------------------------|---|--|--|
| | ur Name:Ying Che | | |
| Ma | anuscript Title: A retrospecti | ive analysis of prognostic f | actors for 160 patients with stage III small cell lung cancer |
| M | anuscript number (if known) | :APM-21-50-CL | |
| | | | |
| rel pa to rel | ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, | manuscript. "Related" mede e affected by the content on necessarily indicate a bias. it is preferable that you do | relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so. ps/activities/interests as they relate to the current |
| to | | ension, you should declare | defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. |
| | item #1 below, report all su e time frame for disclosure i | | d in this manuscript without time limit. For all other items, |
| | | Name all entities with | Specifications/Comments |
| | | whom you have this | (e.g., if payments were made to you or to your |
| | | relationship or indicate | institution) |
| | | none (add rows as | |
| | | needed) | |
| | | Time frame: Since the initia | l planning of the work |
| 1 | All support for the present | XNone | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) No time limit for this item. | | |
| | No time innit for this item. | | |
| | | | |
| | | T: f | 26 manuha |
|) | Cronto or contracts from | Time frame: past | 36 MONTAS |
| <u> </u> | Grants or contracts from any entity (if not indicated | XNone | |
| | in item #1 above). | | |
| 3 | · | V None | |
| י | Royalties or licenses | XNone | |
| | | | |
| 1 | Consulting fees | X None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | XNone | |
|-----|---|---|---|
| | manuscript writing or educational events | | |
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | XNone | |
| | F 2 | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| 10 | Advisory Board Leadership or fiduciary role | Y N | |
| 10 | in other board, society, | XNone | |
| | committee or advocacy | | |
| | group, paid or unpaid | | _ |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, | X None | |
| 12 | materials, drugs, medical | XNone | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |
| Dle | ase summarize the above c | onflict of interest in the following box: | |
| | ase summarize the above t | onner of interest in the following box. | 7 |
| | None | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | ╛ |